glp-1/gip receptor agonist GLP-1 agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Triple GLP-1 / GIP /

doi: 10.1186/s12929-024-00996-w 54 XingJZhangJWangJ

PPAR can upregulate genes involved in fatty acid transport, as well as the fatty acid -oxidation process related to the mitochondria and peroxisomal, to facilitate the intake, utilization, and catabolism of fatty acid (158160), and the mechanism behind this may be an increase in both number and function of mitochondria, leading to a reduction in lipid accumulation (161163)

Furthermore, the interaction with PS particles has been correlated with the activation of pathways of DNA damage and cell death

CJC-1295 with DAC has a half-life of approximately 68 days

MDA: Malondialdehyde